Accessibility Menu
Allergy Therapeutics Plc logo

Allergy Therapeutics Plc(OTC) AGYTF

Market Cap$949.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-92%
5 Year-35%
1 Year+76%
1 Month+15%
$0.15
+0.00%
+0.00Today
Allergy Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 0.152026-07-02
Allergy Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+15.38%USD 0.132026-06-02
1 month+15.38%USD 0.132026-06-02
3 month+36.36%USD 0.112026-03-31
Year to date+36.36%USD 0.112025-10-22
1 year+76.47%USD 0.092025-04-23
3 year-14.29%USD 0.182023-04-03
5 year-34.78%USD 0.232021-06-29
Since inception-92.11%USD 1.902004-12-23

Allergy Therapeutics Plc Financials at a Glance

Market Cap

$949.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£122.41M

Net Income (TTM)

-£84.56M

EPS (TTM)

-$0.01

P/E Ratio

-11.54

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$0.15

Volume

7,142

Open

$0.15

Previous Close

$0.15

Daily Range

$0.15 - $0.15

52-Week Range

$0.09 - $0.15

Estimated Earnings Date

Sep 30, 2026

AGYTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Allergy Therapeutics Plc

Allergy Therapeutics plc is a biotechnology firm focused on developing innovative treatments for allergic conditions. The company specializes in allergen-specific immunotherapies, offering both injectable and sublingual formulations to address various allergies.

Products and Services
  • Allergen-specific immunotherapies for pollen-related allergies
  • Diagnostic tools for allergy identification
  • Innovative vaccines targeting multiple allergens
Growth Outlook
  • Recent revenue of $36.27 million shows a strong upward trend
  • Expansion into new markets across Europe enhances growth potential
  • Active development of new allergy vaccines supports long-term growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of $130.5 million indicates solid performance
  • Recent quarterly net income loss of $19.91 million reflects ongoing investment in R&D
  • Current ratio of 1.13 suggests adequate short-term financial health
Allergy Therapeutics plc is positioned in the healthcare sector, specifically within drug manufacturing for specialty and generic treatments. The company has a diverse product portfolio that includes well-known brands like Pollinex Quattro and Oralvac, which cater to various allergic conditions. The recent revenue growth and strategic market expansion indicate a promising trajectory for the company. Despite facing net income losses, the focus on research and development is expected to yield innovative solutions in the allergy treatment space. The current financial ratios suggest a stable position, making Allergy Therapeutics an intriguing option for potential investors interested in the biotechnology sector.
AI Generated • Aug 8, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

612

CEO

Manuel Llobet, MBA

Website

www.allergytherapeutics.com

Headquarters

Worthing, WSX BN14 8SA, GB

AGYTF Financials

Key Financial Metrics (TTM)

Gross Margin

41.17%

Operating Margin

-60.23%

Net Income Margin

-85.46%

Return on Equity

409.00%

Return on Capital

-131.69%

Return on Assets

-68.96%

Earnings Yield

-8.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$949.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.33B

Volume

7.14K

Avg. Volume

597.492

Financials (TTM)

Gross Profit

£59.40M

Operating Income

-£57.90M

EBITDA

-£63.73M

Operating Cash Flow

-£61.77M

Capital Expenditure

-£7.87M

Free Cash Flow

-£69.64M

Cash & ST Invst.

£10.08M

Total Debt

£26.75M

Allergy Therapeutics Plc Performance Analysis

Allergy Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30GBP 96,730,640N/A
20232023-06-30GBP 71,673,044-25.9%
20242024-06-30GBP 69,490,775-3.0%
20252025-06-30GBP 71,210,2572.5%
Allergy Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-35.6%
Q22024-12-3157.3%
Q42025-06-30-10.4%
Q22025-12-3119.0%
Allergy Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30GBP -0.01N/A
20232023-06-30GBP -0.04171.8%
20242024-06-30GBP -0.01-63.5%
20252025-06-30GBP -0.01-16.2%
Allergy Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3010.3%
Q22024-12-3155.8%
Q42025-06-30-265.2%
Q22025-12-3154.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£36.27M

+8.0%

Gross Profit

£19.32M

-5.9%

Gross Margin

53.26%

N/A

Market Cap

$949.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.55M

N/A

Employees

612

N/A

Net Income

-£19.91M

-27.2%

EBITDA

-£9.76M

-4.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£10.08M

-25.4%

Total Debt

£26.75M

+171.6%

Accounts Receivable

£10.98M

+10.5%

Inventory

£13.79M

+15.9%

Long Term Debt

£24.79M

+206.0%

Short Term Debt

£1.96M

+12.2%

Return on Assets

-68.96%

N/A

Return on Invested Capital

-88.54%

N/A

Free Cash Flow

-£14.51M

-14.8%

Operating Cash Flow

-£11.71M

-8.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOIRFBoiron S.A.
$31.50+0.00%
VRNOFVerano Holdings Corp.
$1.30+8.33%
CRLBFCresco Labs Inc.
$0.80+0.74%
LBLTFLattice Biologics Ltd.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About AGYTF

What is the current price of Allergy Therapeutics Plc?

Allergy Therapeutics Plc is trading at $0.15 per share.

What is the 52-week range for Allergy Therapeutics Plc?

Over the past 52 weeks, Allergy Therapeutics Plc has traded between $0.09 and $0.15.

How much debt does Allergy Therapeutics Plc have?

As of the most recent reporting period, Allergy Therapeutics Plc reported total debt of £82.34M.

How much cash does Allergy Therapeutics Plc have on hand?

Allergy Therapeutics Plc reported £17.53M in cash and cash equivalents in its most recent financial results.

What is Allergy Therapeutics Plc’s dividend yield?

Allergy Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services